AWT020

BIOLOGICAL3 trials

Sponsors

Anwita Biosciences, Shanghai Junshi Bioscience Co., Ltd.

Conditions

Advanced CancerAdvanced Cancers (Solid Tumors)Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor

Phase 1

Phase 1 Study of AWT020 in Advanced Cancer

RecruitingNCT06092580

Anwita BiosciencesAdvanced Cancer

Start: 2023-09-15End: 2026-09-30Target: 60Updated: 2025-09-02

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

RecruitingNCT06839105

Shanghai Junshi Bioscience Co., Ltd.Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor

Start: 2025-02-21End: 2028-04-30Target: 214Updated: 2026-07-02

A Study of AWT020 in Participants With Advanced Solid Tumors

RecruitingNCT07822919

Anwita BiosciencesAdvanced Cancers (Solid Tumors)

Start: 2026-09-11End: 2029-02-01Target: 96Updated: 2026-09-23

Related Papers

First-in-human study of AWT020, a bifunctional anti-PD-1/IL-2 fusion protein, in patients with advanced cancer.

Journal of Clinical Oncology2025-05-28